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Abstract
Background: Incidence of acute rheumatic fever (ARF) and prevalence of rheumatic heart disease (RHD) in the
Pacific region, including New Caledonia, are amongst the highest in the world. The main priority of long-term
management of ARF or RHD is to ensure secondary prophylaxis is adhered to. The objectives of this study were to
evaluate rates of adherence in people receiving antibiotic prophylaxis by intramuscular injections of penicillin in
Lifou and to determine the factors associated with a poor adherence in this population.
Methods: We conducted a retrospective cohort study and we included 70 patients receiving injections of antibiotic
prophylaxis to prevent ARF recurrence on the island of Lifou. Patients were classified as “good-adherent” when the
rate of adherence was ≥80% of the expected injections and as “poor-adherent” when it was <80%. Statistical
analysis to identify factors associated with adherence was performed using a multivariate logistic regression model.
Results: Our study showed that 46% of patients from Lifou receiving antibiotic prophylaxis for ARF or RHD had a
rate of adherence <80% and were therefore at high risk of recurrence of ARF. Three independent factors were
protective against poor adherence: a household with more than five people (odds ratio, 0.25; 95% confidence
interval [CI], 0.08 to 0.75), a previous medical history of symptomatic ARF (odds ratio, 0.20; 95% CI, 0.04 to 0.98) and
an adequate healthcare coverage (odds ratio, 0.21; 95% CI 0.06 to 0.72).
Conclusions: To improve adherence to secondary prophylaxis in Lifou, we therefore propose the following
recommendations arising from the results of this study: i) identifying patients receiving antibiotic prophylaxis
without medical history of ARF to strengthen their therapeutic education and ii) improving the medical coverage in
patients with ARF or RHD. We also recommend that the nurse designated for the ARF prevention program in Lifou
coordinate an active recall system based on an updated local register. But the key point to improve adherence
among Melanesian patients is probably to give appropriate information regarding the disease and the treatment,
taking into account the Melanesian perceptions of the disease.
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Background
Acute rheumatic fever (ARF) and rheumatic heart disease
(RHD) represent the first cause of cardiac mortality
among children and young people in developing countries
[1]. The worldwide prevalence of RHD is estimated at 15.6
million people, with an annual incidence of ARF of
470,000. The burden of mortality still concerns 230,000
people per annum, caused by infective endocarditis and
heart failures [2].
Since the 1980s, recommendations of the World Health
Organization (WHO) promote secondary prevention as
the cornerstone of control programs [3]. Secondary pre-
vention of rheumatic fever is defined as the continuous
administration of specific antibiotics to patients with a pre-
vious attack of rheumatic fever, or well-documented
rheumatic heart disease. The purpose is to prevent
colonization or infection of the upper respiratory tract with
group A beta-hemolytic streptococci and the development
of recurrent attacks of rheumatic fever [4]. Secondary pre-
vention is considered to be the most cost-effective strategy
to reduce mortality and morbidity [4]. Based on local and
central registers, its objectives are to identify new cases of
ARF and RHD, standardize and improve the diagnosis,
management and follow-up of the patients, train health
agents and communities to ARF, and maximize the admin-
istration of secondary prophylaxis [5,6]. The recommended
secondary prophylaxis consists of intramuscular injections
of benzathine benzylpenicillin G (BPG), every three to four
weeks, the dosage being adapted to patient’s weight [7].
Patients with proven penicillin allergy should be managed
with twice-daily oral erythromycin [4]. Recommendations
on the frequency of intramuscular injections and the dur-
ation of secondary prophylaxis vary between authorities.
The WHO does not specify whether injections should be
administered every 3 weeks or every 4 weeks. The appro-
priate duration of secondary prophylaxis is determined by
a number of factors, including age, time since the last epi-
sode of ARF, ongoing risk of streptococcal infections and
potential harm from recurrent ARF [4,8,9]. Its effectiveness
in reducing rates of streptococcal pharyngitis, recurrences
of ARF and the progression of RHD is clearly assessed, and
might even lead to a regression of mild to moderate valvu-
lar lesions within a decade [10-12].
Nevertheless, poor adherence to treatment is the main
impediment to secondary prevention. Defined as the
concordance between the patient’s behavior and the care
provider’s recommendations [13], adherence is a rate
that can range from 0 to more than 100% [14]. Global
adherence to treatment of chronic diseases in developed
countries averages only 50%, particularly affecting the
poor population. As many factors interact and interfere
with adherence, it is considered as a multidimensional
phenomenon [15].
Multiple measures of adherence to secondary prophy-
laxis of ARF were assessed since the 1970s, using various
tools, such as the annual rate of BPG injections, the per-
centage of positive-for-penicillin urines, or the time interval
and attendance at visiting specialist and echocardiographic
appointments, but only few studies aimed at determining
the factors associated to adherence [16-21]. Even though
the level of adherence required to prevent further episodes
of ARF is not known, the objective is to reach 100% of the
annual expected BPG injections, with a recommended
benchmark of 80% [9]. Patients receiving less than 80% of
prescribed doses are considered at high risk of recurrence
of ARF [6].
Figure 1 Flow chart of the enrollment of subjects, Lifou, New Caledonia, 2011.
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It is in the Pacific region that the highest prevalences
of RHD in the world are found [22]. In New Caledonia,
the prevalence of RHD was estimated at 9/1,000 in
school-children in their fourth year of primary school
[23] but there are no data relating to the level of adher-
ence. The objectives of this study were to evaluate rates
of adherence in people receiving BPG injections prophy-
laxis in Lifou and to determine the factors associated
with a poor adherence in this population.
Methods
Ethics statement
Ethical clearance was obtained from the Public Health
and Social Agency of New Caledonia (Agence Sanitaire
et Sociale de la Nouvelle-Calédonie). The study was also
approved by the French consultative committee for the
data processing in health research (Comité Consultatif sur
le Traitement de l'Information en matière de Recherche
dans le domaine de la Santé, CCTIRS). Informed written
consent was obtained from adults or from the child’s par-
ents before conducting the interviews and after reading
them information about the study. All data analyzed were
confidential.
Setting
The study took place in the tropical island of Lifou,
located 100 km from New Caledonia’s main island, a
French territory in the South Pacific. With a surface of
1,200 km2 and a population of 8,627 inhabitants (Census
2009, New Caledonian Institute for Statistics and Econom-
ics, ISEE), Lifou is divided into three districts and 37
tribes. Population is comprised of 96% of Melanesian
whose income comes mainly from agriculture. According
to ISEE 52% of the households are considered poor by the
local criteria (Monthly household income < 75,000 XPF =
800 USD). Dwellings can be concrete, semi-concrete or
traditional huts, mostly water and electricity-supplied. The
main religion is Protestantism.The health care system
includes two public health centers (We and Xepenehe),
two private general practitioners (GPs) and a few private
nurses. There is a nurse designated for the ARF preven-
tion program, in Lifou acting as a link between the health
agency in charge of the ARF prevention program based in
the main island and local health professionals. There are
no cardiologists or radiologists. Patients sometimes need
to travel to the main island of New Caledonia by plane or
ferry to attend the recommended annual echocardiog-
raphy. Social security coverage is provided if the RHD is
declared to the social welfare system. Patient with an ad-
equate healthcare coverage do not have to advance med-
ical expenses for the access to a cardiologist for regular
follow up visits. . Otherwise, a copayment is required. Ad-
ministration of BPG injections is free of charge, regardless
of the patient’s medical coverage.
Study design
We conducted a retrospective cohort study in Lifou and
we included all patients receiving BPG injections prophy-
laxis over at least a period of 12 consecutive months, from
the 1st of January 2011 to the 31st of December 2011.
The WHO adherence project has adopted the following
definition of adherence to long-term therapy: « the extent
to which a person's behaviour - taking medication, follow-
ing a diet, and/or executing lifestyle changes, corresponds
with agreed recommendations from a health care provider
[15]. In our study, the rate of adherence was obtained by
dividing the number of injections of BPG administered by
Table 1 Characteristics of the 70 patients receiving
antibiotic prophylaxis to prevent acute rheumatic fever
recurrence, Lifou, New Caledonia, 2011





















≥150,000 XPF (1,600 USD) / month 43/67 (64)





History of acute rheumatic fever
No 13/70 (19)
Yes 57/70 (81)
Diagnosis of rheumatic heart disease
No 16/70 (23)
Yes 54/70 (77)
* Mother or father of Melanesian origin.
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the number of the expected injections in 2011 (n = 17),
considering a frequency of 3 weeks. This 3 weekly fre-
quency is the frequency recommended by the Caledonian
health agency in charge of the ARF prevention program at
the time of this study. Patients were then classified as
“poor-adherent” when the rate of adherence was <80% of
the expected injections and as “good-adherent” when it
was ≥80% [6,9].
Data collection
Data were collected from patients’ medical records and
through a standardized questionnaire administered face to
face by a single interviewer (BG). The questionnaire went
through a pilot phase for 10 persons. For very young chil-
dren, one of the parents at least was interviewed. For chil-
dren aged less than 16 years old and able to understand
the questions, we interviewed the child and one of his par-
ents at least. We collected information about demographic
and socio-economic characteristics, health care team and
system-related factors, condition-related factors, therapy-
related factors and patient related-factors, according to
WHO recommendations [24]. All questions were close-
ended with binary choices. To prevent information bias,
we limited questions (n = 3) referring to patient recall
(minimal information on ARF/RHD, reason for not taking
the medication, hospitalization at diagnosis).
Statistical analysis
Statistical analysis was performed by using Stata Statistical
Software Release 11 (StataCorp. 2009, College Station, TX:
StataCorp LP). Continuous variables were summarized
using means ± standard deviation or median and inter-
quartile range (IQR). Frequencies of potential factors be-
tween good-adherent and poor-adherent patients were
compared by Fisher’s exact test. All statistical tests were
two-tailed, and p values of less than 0.05 were considered
to indicate statistical significance. We used logistic regres-
sion to examine the association between potential factors
and the likelihood of a favorable outcome. Odds ratios
(OR) and 95 percent confidence intervals (CI) were used to
quantify the strength of these associations. Variables with a
two-sided p value <0.25 were introduced in the multivari-
able logistic regression model. Multiplicative interactions
were tested for their significance at the 0.05 level. A back-
ward stepwise method was used to develop an optimal
multivariable logistic model. Stata software includes auto-
matic checks for collinearity. The Hosmer-Lemeshow
goodness-of-fit test was used to evaluate the final regres-
sion model.
Results
Baseline characteristics of the population study
A total of 81 persons with a history of ARF or RHD and
taking antibiotic prophylaxis in 2011 were identified in
Lifou, given a prevalence of 9.4/1,000 inhabitants. Among
them, 11 were excluded: three were unreachable, three
took oral antibiotic prophylaxis and five started antibiotic
in the year 2011 (Figure 1). In the end, 70 patients were
included in the study and the participation rate was 100%.
The mean age of our population sample was 22.3 ±
11.6 years, 43% were children aged less than 16 years old
and 63% were female. Baseline characteristics of our popu-
lation are presented in Table 1.
Our study showed that there were 38 good-adherent
patients (54%) and 32 poor-adherent patients (46%)
(Figure 2). The mean adherence to secondary prophy-
laxis was 77% ± 22 and the median adherence was 82.2%
(IQR 76.5- 94.1). The median number of injections was
14 (range 2–18).
Public health centers followed up 65 patients, GPs fol-
lowed up the remaining five. The mean distance between
the house and the nearest health center was 12 km ±10.8.
Figure 2 Rates of adherence in patients receiving antibiotic prophylaxis for acute rheumatic fever recurrence, Lifou, New
Caledonia, 2011.
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Demographic and socio-economic characteristics
Age <16 years old 0.092
No 18/38 (47) 22/32 (69)
Yes 20/38 (53) 10/32 (31)
Male sex 0.215
No 21/38 (55) 23/32 (72)
Yes 17/38 (45) 9/32 (28)
Concrete dwelling 0.466
No 25/38 (66) 18/32 (56)
Yes 13/38 (34) 14/32 (44)
Number of persons in the household≥ 6 0.054
No 13/38 (24) 19/32 (59)
Yes 25/38 (66) 13/32 (41)
Other case(s) of ARF in the household 0.320
No 30/37 (81) 29/32 (91)
Yes 7/37 (19) 3/32 (9)
Household income <150 000 CFP (1,600 USD)/month 1
No 14/38 (37) 10/29 (34)
Yes 24/38 (63) 19/29 (66)
Health care team and system-related characteristics
Follow up of ARF/RHD in a health center 1
No 3/38 (8) 2/32 (6)
Yes 35/38 (92) 30/32 (94)
Follow up of ARF/RHD in the health center of Xépénéhé 0.140
No 13/35 (37) 17/30 (57)
Yes 22/35 (63) 13/30 (43)
Distance between the residence and the nearest health center >5 km 0.116
No 14/38 (37) 6/32 (19)
Yes 24/37 (63) 26/32 (81)
Duration for an injection >3 h § 0.257
No 23/29 (79) 24/26 (92)
Yes 6/29 (21) 2/26 (8)
BPG injections’ recall system ¶ 0.042
No 37/37 (100) 28/32 (88)
Yes 0/37 (0) 4/32 (12)
Adequate healthcare coverage 0.070
No 8/37 (22) 14/32 (44)
Yes 29/37 (78) 18/32 (56)
Condition-related characteristics
Previous history of ARF 0.121
No 10/38 (26) 3/32 (9)
Yes 28/38 (74) 29/32 (91)
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A fifth (21%) of the patients was administered injections at
home. A total of 57 patients had a history of ARF, including
3 cases of chorea. Among the 54 patients with a previous
history of RHD, 8 were diagnosed during an echographic
screening. The mean duration of treatment was 6.4 ±
4.9 years. The majority of people trusted the treatment (94%)
and didn’t want to switch for an oral antibiotic prophylaxis
(85%). Results of the univariate analysis comparing good-
adherent and poor-adherent are presented in Table 2.
Multivariate analysis
The logistic non-conditional multivariate analysis identified
three independent protective factors of poor adherence: a
household with more than five people (OR, 0.25; 95% CI,
0.08 to 0.75), a previous medical history of symptomatic
ARF (OR, 0.20; 95% CI, 0.04 to 0.98) and an adequate
healthcare coverage (OR, 0.21; 95% CI 0.06 to 0.72)
(Table 3).
Discussion
To our knowledge, this is the first study evaluating rates
and determinants of adherence to secondary antibiotic
prophylaxis for ARF recurrence in New Caledonia. Our
study showed that there were 38 good-adherent patients
(54%) and 32 poor-adherent patients (46%) in Lifou.
This means that 46% of these patients with a previous
Table 2 Univariate analysis comparing good-adherent to poor-adherent patients, Lifou, New Caledonia, 2011
(Continued)
Previous history of RHD 1
No 9/38 (24) 7/32 (22)
Yes 29/38 (76) 25/32 (78)
Severe RHD at diagnosis** 1
No 25/29 (86) 19/22 (86)
Yes 4/29 (14) 3/22 (14)
Hospitalization at diagnosis of ARF or RHD 0.813
No 18/36 (50) 17/32 (53)
Yes 18/36 (50) 15/32 (47)
Therapy-related characteristics
Treatment duration >2 years 0.743
No 5/37 (14) 6/32 (19)
Yes 32/37 (86) 26/32 (81)
Severe pain from BPG injection¶ 0.130
No 36/38 (95) 26/32 (81)
Yes 2/38 (5) 6/32 (19)
Desire for oral treatment¶ 1
No 32/38 (84) 24/28 (86)
Yes 6/38 (16) 4/28 (14)
Confidence in treatment¶ 0.316
No 1/36 (3) 3/29 (10)
Yes 35/36 (97) 26/29 (90)
Patient-related characteristics
Protestant religion 0.602
No 10/38 (26) 11/32 (34)
Yes 28/38 (74) 21/32 (66)
Knowledge of treatment’s objectives 1
No 2/32 (6) 2/27 (7)
Yes 30/32 (94) 25/27 (93)
CI denotes confidence interval, ARF denotes acute rheumatic fever and RHD denotes rheumatic heart disease.
*P values were calculated with the use of Fisher’s exact test for categorical variables and Student’s test for continue variables.
§ The duration includes transport from home to health center, way and back. Patients having injections at home were excluded.
¶ Declarative information.
** The classification of severity was obtained by echocardiography medical records.
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history of ARF or RHD and receiving BPG injections
were at high risk of recurrence of ARF.
The mean and median rate of adherence we found (77%
and 82.2% respectively) was lower than the one observed
in India par Kumar et al. (mean adherence >90%), but was
higher than those assessed in Australia by Stewart et al.
(median rate of injections 54%), by Eissa et al. in a remote
Top End Aboriginal community (58% of patients received
<80% of doses), by Mincham et al. in the Kimberley region
in Western Australia (median adherence = 67%) and by
Seckeler et al. in Northern Mariana Islands (median ad-
herence = 69.2%) [16,18,19,21,25]. A study conducted in
Egypt showed that 64.6% of patients had an adherence
≥84%, nevertheless the study samples can hardly be com-
pared (20% of children under oral antibioprophylaxis,
injections of BPG delivered every 2 weeks) [17]. Ehmke
et al.'s study in Iowa, where the overall adherence was
64.6%, presents the same objections to comparison: paedi-
atric population, oral antibioprophylaxis [26].
The wide range of indicators used in these different
studies makes comparison particularly difficult and high-
lights the necessity of standardized indicators to evaluate
adherence.
In our study, the multivariate analysis could determine
three independent factors protectors of poor adherence:
a demographic factor, ≥6 individuals in the household; a
health system-related factor, an adequate healthcare
coverage; a condition-related factor, a previous history of
symptomatic ARF. Two studies, conducted in the USA,
tried to determine an association between the number of
individuals of the household and the adherence. Gordis
et al. in 1969, and Ehmke et al. in 1980 found that a
large number of siblings was a risk factor of poor
adherence [26,27]. In our study, we postulate that a large
number of siblings in the household could improve the
adherence probably because of the presence of a big
brother or sister. They could accompany the child to the
health center or take care of the household during the
time of the consultation. This hypothesis is consistent with
Gordis et al. study in which being unaccompanied by par-
ent at clinical visits was associated with poor adherence.
Mincham and Harrington, in two qualitative studies con-
ducted in Australia, showed that an active recall system
was a major determinant of adherence [28,29]. This sec-
ondary prevention strategy is indeed highly recommended
by the WHO and the World Heart Federation [4,6].
The association between the cost of medication and a
poor adherence affects particularly low income popula-
tions [15,30-32]. To our knowledge no study ever ana-
lyzed this association in secondary prophylaxis to ARF
and RHD, probably because it is usually free of charge in
most countries. In Lifou, BPG injections are free but the
copayment required for cardiologist reviews and transports
to the cardiologist might have led to a negative perception
of the health system and a feeling of not “belonging” to the
health service. According to Harrington and Mincham,
those representations of health system were responsible of
poor adherence among Aboriginal patients [28,29]. An ad-
equate healthcare coverage might be the consequence of a
good adherence. Indeed, good adherent patients having
frequent interactions with health staff could have a better
track of their administrative and medical record.
Patients with a previous history of symptomatic ARF
had a better adherence than patients who were diagnosed
with RHD without history of ARF. It is described that
among chronic diseases, asymptomatic diseases (diabetes,
hypertension, osteoporosis. . .) are more likely to generate
poor adherence [15]. Patient’s perception of the disease
gets modified by the existence of symptoms and the level
of disability. Gordis et al. determined that having ARF
with “no restriction of activity” was a risk factor of poor
adherence among children [33]. Fear of recurrence of in-
tense and painful symptoms might enhance adherence,
unlike those diagnosed with RHD without history of ARF.
Health education and sensitization in order to modify
risks perception shall therefore be promoted.
Our retrospective cohort study of patients receiving anti-
biotic prophylaxis for ARF recurrence in Lifou was quite
exhaustive; three patients only could not be contacted. A
single investigator (BG) interviewed patients and collected
data, therefore limiting the risk of variability. The study was
led on a small island where all the health structures could
be visited, which facilitated the data collection. By screening
data, this study allowed us to register three new patients in
the local register, to realize numerous demands for full
medical coverage, to update medical and personal data and
to provide information to cease two patients’ antibiotic
Table 3 Determinants of poor adherence to antibiotic





Number of persons in the household ≥6 0.014
No 1
Yes 0.25 (0.08 – 0.75)
Previous history of ARF 0.047
No 1
Yes 0.20 (0.04 – 0.98)
Adequate healthcare coverage 0.013
No 1
Yes 0.21 (0.06 – 0.72)
CI denotes confidence interval, ARF denotes acute rheumatic fever.
*p values were calculated with the use of logistic-regression analysis.
Variables candidates were : age <16 years old, male sex, distance from nearest
health center >5 km, BPG injections’ recall system, follow up of ARF/RHD in
health center of Xépénéhé, severe pain from BPG injection, number of persons
in the household ≥6, previous history of ARF, full medical coverage.
p value was 0.67 by the Hosmer–Lemeshow test for goodness of fit.
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prophylaxis. Nevertheless, one of the limitations of this
study, beside its retrospective design, was the sample size,
resulting in a lack of statistical power. Another limitation
was that we were not able to perform a sub-group analysis
comparing children aged less than16 years and adults be-
cause of the small sample size giving a lack of power.
Conclusions
To improve adherence to secondary prophylaxis in
Lifou, we therefore propose the following recommenda-
tions arising from the results of this study: i) identifying
patients receiving antibiotic prophylaxis without medical
history of ARF to strengthen their therapeutic education
and ii) improving the medical coverage in patients with
ARF or RHD. Moreover, regarding the difficulty to iden-
tify ARF/RHD patients and to collect data on the dates
of injections during the study, we also recommend that
the nurse designated for the ARF prevention program in
Lifou coordinate an active recall system based on an
updated local register. Further epidemiologic research to
better answer the question as to what makes some
patients adhere to their injection and others not are
needed. This might include a study on the main island
of New Caledonia with a bigger sample size and a rando-
mized study evaluating an intervention. But the key
point to improve adherence among Melanesian patients
is probably to give appropriate information regarding
the disease and the treatment, taking into account the
Melanesian perceptions of the disease.
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